![Derek Gallacher](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Derek Gallacher
Corporate Officer/Principal en Javelin Pharmaceuticals, Inc. .
Perfil
Derek Gallacher is a Managing Director of European for Javelin Pharmaceuticals, Inc. He was Director of European Analgesic Marketing and European Marketing Director for Mundipharma International Ltd.
Mr. Gallacher has 20 years of pharmaceutical experience.
Previously, he worked with Beecham and Glaxo Pharmaceuticals and Napp Pharmaceuticals Ltd.
Cargos activos de Derek Gallacher
Empresas | Cargo | Inicio |
---|---|---|
Javelin Pharmaceuticals, Inc.
![]() Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Javelin Pharmaceuticals, Inc.
![]() Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Derek Gallacher